Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.
Eun-Joo ShinJi Hoon JeongYeonggwang HwangNaveen SharmaDuy-Khanh DangBao-Trong NguyenSeung-Yeol NahChoon-Gon JangGuoying BingToshitaka NabeshimaHyoung-Chun KimPublished in: Archives of pharmacal research (2021)
Parkinson's disease (PD) is a progressive neurodegenerative disease with a high prevalence, approximately 1 % in the elderly population. Numerous studies have demonstrated that methamphetamine (MA) intoxication caused the neurological deficits and nigrostriatal damage seen in Parkinsonian conditions, and subsequent rodent studies have found that neurotoxic binge administration of MA reproduced PD-like features, in terms of its symptomatology and pathology. Several anti-Parkinsonian medications have been shown to attenuate the motor impairments and dopaminergic damage induced by MA. In addition, it has been recognized that mitochondrial dysfunction, oxidative stress, pro-apoptosis, proteasomal/autophagic impairment, and neuroinflammation play important roles in inducing MA neurotoxicity. Importantly, MA neurotoxicity has been shown to share a common mechanism of dopaminergic toxicity with that of PD pathogenesis. This review describes the major findings on the neuropathological features and underlying neurotoxic mechanisms induced by MA and compares them with Parkinsonian pathogenesis. Taken together, it is suggested that neurotoxic binge-type administration of MA in rodents is a valid animal model for PD that may provide knowledge on the neuropathogenesis of PD.
Keyphrases
- oxidative stress
- diabetic rats
- traumatic brain injury
- cell death
- healthcare
- risk factors
- induced apoptosis
- inflammatory response
- lipopolysaccharide induced
- ischemia reperfusion injury
- brain injury
- anti inflammatory
- endothelial cells
- cerebral ischemia
- heat stress
- cognitive impairment
- middle aged
- signaling pathway
- high glucose
- cell cycle arrest
- subarachnoid hemorrhage